-- phpMyAdmin SQL Dump
-- version 4.5.1
-- http://www.phpmyadmin.net
--
-- Host: 127.0.0.1
-- Generation Time: Apr 09, 2017 at 05:22 PM
-- Server version: 10.1.16-MariaDB
-- PHP Version: 5.6.24

SET SQL_MODE = "NO_AUTO_VALUE_ON_ZERO";
SET time_zone = "+00:00";


/*!40101 SET @OLD_CHARACTER_SET_CLIENT=@@CHARACTER_SET_CLIENT */;
/*!40101 SET @OLD_CHARACTER_SET_RESULTS=@@CHARACTER_SET_RESULTS */;
/*!40101 SET @OLD_COLLATION_CONNECTION=@@COLLATION_CONNECTION */;
/*!40101 SET NAMES utf8mb4 */;

--
-- Database: `medications`
--

-- --------------------------------------------------------

--
-- Table structure for table `medication_table`
--

CREATE TABLE `medication_table` (
  `CName` varchar(100) NOT NULL,
  `Name` varchar(100) NOT NULL,
  `SName` varchar(100) NOT NULL,
  `Type` varchar(100) NOT NULL,
  `Formulations (Suspension)` text NOT NULL,
  `Formulations (Tablet)` text NOT NULL,
  `Formulations (BOTH)` text NOT NULL,
  `Fixed Dose Combination Tablets` text NOT NULL,
  `Treatment of HIV Infection` text NOT NULL,
  `Neonate (birth to <3 months)` text NOT NULL,
  `Infant (3 months to 8 months)` text NOT NULL,
  `Pediatric (8 months to 6 years old)` text NOT NULL,
  `Adolescent (6 years old - 17 years old)` text NOT NULL,
  `Adult (18 years old+)` text NOT NULL,
  `Special Instructions` text NOT NULL
) ENGINE=InnoDB DEFAULT CHARSET=latin1;

--
-- Dumping data for table `medication_table`
--

INSERT INTO `medication_table` (`CName`, `Name`, `SName`, `Type`, `Formulations (Suspension)`, `Formulations (Tablet)`, `Formulations (BOTH)`, `Fixed Dose Combination Tablets`, `Treatment of HIV Infection`, `Neonate (birth to <3 months)`, `Infant (3 months to 8 months)`, `Pediatric (8 months to 6 years old)`, `Adolescent (6 years old - 17 years old)`, `Adult (18 years old+)`, `Special Instructions`) VALUES
('a1', 'Abacavir (ABC, Ziagen)', 'Abacavir', 'NRTI', '(Oral Solution): 20 mg/mL', '(Tablets): 300 mg', '(Pediatric Oral Solution): 20 mg/mL\r\n(Tablets): 300 mg', '[Epzicom] Abacavir 600 mg + Lamivudine 300 mg\r\n[Trizivir] Abacavir 300 mg + Lamivudine 150 mg + zidovudine 300 mg\r\n[Triumeq] Abacavir 600 mg + Dolutegravir 50 mg + Lamivudine 300 mg', '', 'not approved', '16 mg/kg daily (Oral Solution)', '16 mg/kg daily (Oral Solution)', '600 mg daily if weight 25 kg or above\r\n[Trizivir] one tablet twice daily if weight 40 kg or above\r\n[Epzicom] one tablet once daily if weight 25 kg or above\r\n[Triumeq] one tablet once daily if weight 40 kg or above', '600 mg daily\r\n[Trizivir] one tablet twice daily\r\n[Epzicom] one tablet once daily\r\n[Triumeq]  one tablet once daily', 'Patients positive for the HLA-B* 5701 allele should not be given abacavir. \r\n'),
('a2', 'Didanosine (ddl, Videx)', 'Didanosine', 'NRTI (rare)', '(Videx Pediatric Powder for Oral Solution): Reconstituted 10 mg/mL', '(EC Beadlets): 125 mg, 200 mg, 250 mg, 400 mg (Generic Didanosine Delayed-Release Capsules): 125 mg, 200 mg, 250 mg, 400 mg (Tablet for Oral Suspension): 100 mg, 150 mg, 200 mg','(Tablet for Oral Suspension): 100 mg, 150 mg, 200 mg''(Videx Pediatric Powder for Oral Solution): Reconstituted 10 mg/mL\r\n(EC Beadlets): 125 mg, 200 mg, 250 mg, 400 mg\r\n(Generic Didanosine Delayed-Release Capsules): 125 mg, 200 mg, 250 mg, 400 mg\r\n(Tablet for Oral Suspension): 100 mg, 150 mg, 200 mg', '', '', '50 mg/m^2 of BSA every 12 hours', '100 mg/ mg^2 of BSA every 12 hours', '120 mg/m^2 of BSA every 12 hours (Oral Solution)', 'EC Beadlets or Generic Capsules \r\nfor ages 6-18 years:\r\n20 kg to below 25 kg: 200 mg once daily\r\n25 kg to below 60 kg: 250 mg once daily\r\n60 kg and above: 400 mg once daily', 'EC Beadlets or Generic Capsules:\r\nunder 60 kg: 250 mg once daily\r\n60 kg or above: 400 mg once daily\r\nDidanosine combined with TDF:\r\nbelow 60 kg: 200 mg once daily\r\n60 kg and above: 250 mg once daily\r\n', 'Administration of didanosine on an empty stomach is generally \r\nrecommended.'),
('a3', 'Emtricitabine (FTC, Emtriva)', 'Emtricitabine', '', '(Oral Solution): 10 mg/mL','(Capsules): 200 mg','(Oral Solution): 10 mg/mL\r\n(Capsules): 200 mg', '[Truvada low strength tablet]\r\nEmtricitabine 100 mg + Tenofovir Disoproxil Fumarate (TDF) 150 mg\r\nEmtricitabine 133 mg + TDF 200 mg\r\nEmtricitabine 167 mg + TDF 250 mg\r\n[Descovy] Emtricitabine 200 mg + Tenofovir Alafenamide (TAF) 25 mg\r\n[Atripla] Efavirenz 600 mg + Emtricitabine 200 mg + TDF 300 mg\r\n[Complera] Emtricitabine 200 mg + Rilpivirine 25 mg + TDF 300 mg\r\n[Odefsey] Emtricitabine 200 mg + Rilpivirine 25 mg + TAF 25 mg\r\n[Stribild] Elvitegravir 150 mg + Cobicistat 150 mg + Emtricitabine 200 mg + TDF 300 mg\r\n[Genvoya] Elvitegravir 150 mg + Cobicistat 150 mg + Emtricitabine 200 mg + TAF 10 mg\r\n', '', '2 mg/kg once daily (Oral Solution \r\nfor 0 to under 3 months)\r\n[Truvada tablet]\r\n17 kg to below 22 kg: 100 mg FTC / 150 mg TDF tablet once daily\r\n22 kg to below 28 kg: 133 mg FTC / 200 mg TDF tablet once daily\r\n28 kg to below 35 kg: 167 mg FTC / 250 mg TDF tablet once daily', '6 mg/kg (max dose 240 mg) once daily\r\n(Oral Solution) \r\n200 mg once daily (Capsules if weight \r\nover 33 kg)\r\n[Truvada tablet]\r\n17 kg to below 22 kg: 100 mg FTC / 150 mg TDF tablet once daily\r\n22 kg to below 28 kg: 133 mg FTC / 200 mg TDF tablet once daily\r\n28 kg to below 35 kg: 167 mg FTC / 250 mg TDF tablet once daily', '6 mg/kg (max dose 240 mg) once daily\r\n(Oral Solution) \r\n200 mg once daily (Capsules if weight \r\nover 33 kg)\r\n[Truvada tablet]\r\n17 kg to below 22 kg: 100 mg FTC / 150 mg TDF tablet once daily\r\n22 kg to below 28 kg: 133 mg FTC / 200 mg TDF tablet once daily\r\n28 kg to below 35 kg: 167 mg FTC / 250 mg TDF tablet once daily', '6 mg/kg (max dose 240 mg) once daily\r\n(Oral Solution) \r\n200 mg once daily (Capsules if weight \r\nover 33 kg)\r\n[Truvada tablet]\r\n22 kg to below 28 kg: 133 mg FTC / 200 mg TDF tablet once daily\r\n28 kg to below 35 kg: 167 mg FTC / 250 mg TDF tablet once daily\r\n35 kg and above: 200 mg FTC / 300 mg TDF tablet once daily\r\n[Descovy] above 35 kg: one tablet once daily\r\n[Atripla] aged 12 or over and above 40 kg: one tablet once daily without food\r\n[Complera] above 35 kg: one tablet once daily with a meal of at least\r\n500 calories. Patients must be treatment-naive with baseline plasma RNA \r\nunder 100,000 copies/mL or virologically surpressed patients with no \r\nhistory of virologic failure, resistance to rilpivirine and other ARV drugs, and \r\nwho are currently on their first or second regimen.\r\n[Odefsey] 35 kg or above: one tablet once a day with a meal with at least 500 \r\ncalories. The meal is initial therapy in those with no ARV treatment history with \r\nHIV-1 RNA less or equal to 100,000 copies per mL; or to replace a stable ARV \r\nregimen in those who are viologically surpressed for at least 6 months with no \r\nhisotry of treatment failure and no known substitutions associated with \r\nresistance to the individual components of Odefesey.\r\n[Genvoya] 35 kg or above and aged at least 12 years: one tablet once a day with \r\nfood in ARV treatment-naive patients or to replace the current ARV regimen in \r\nthose who are virologically suppressed (HIV-1 RNA under 50 copies/mL) on \r\na stable ARV regimen for at least 6 months with no history of treatment failure and \r\nno known substitutions associated with resistance to the individual components \r\nof Genvoya.', '240 mg once daily (Oral Solution)\r\n200 mg once daily (Capsules)\r\n[Truvada tablet]\r\n28 kg to below 35 kg: 167 mg FTC / 250 mg TDF tablet once daily\r\n35 kg and above: 200 mg FTC / 300 mg TDF tablet once daily\r\n[Descovy] one tablet once daily\r\n[Atripla] above 40 kg: one tablet once daily without food\r\n[Complera] above 35 kg: one tablet once daily with a meal of at least\r\n500 calories. Patients must be treatment-naive with baseline plasma RNA \r\nunder 100,000 copies/mL or virologically surpressed patients with no \r\nhistory of virologic failure, resistance to rilpivirine and other ARV drugs, and \r\nwho are currently on their first or second regimen.\r\n[Odefsey] 35 kg or above: one tablet once a day with a meal with at least 500 \r\ncalories. The meal is initial therapy in those with no ARV treatment history with \r\nHIV-1 RNA less or equal to 100,000 copies per mL; or to replace a stable ARV \r\nregimen in those who are viologically surpressed for at least 6 months with no \r\nhisotry of treatment failure and no known substitutions associated with \r\nresistance to the individual components of Odefesey.\r\n[Stribild] one tablet once a day in treatment-naive or virologically \r\nsurpressed adults with a meal.\r\n[Genvoya] 35 kg or above and aged at least 12 years: one tablet once a day with \r\nfood in ARV treatment-naive patients or to replace the current ARV regimen in \r\nthose who are virologically suppressed (HIV-1 RNA under 50 copies/mL) on \r\na stable ARV regimen for at least 6 months with no history of treatment failure and \r\nno known substitutions associated with resistance to the individual components \r\nof Genvoya.', 'TAF-containing formulations are not recommended to patients with \r\nestimated creatinine clearance (CrCl) below 30 mL per minute.'),
('a4', 'Lamivudine (3TC, Epivir)', 'Lamivudine', 'NRTI', '(Pediatric Oral Solution): 10 mg/mL (Epivir), 5 mg/mL (Epivir HBV)','(Tablets): 150 mg (scored), 300 mg (generic), 100 mg (Epivir HBV)','(Pediatric Oral Solution): 10 mg/mL (Epivir), 5 mg/mL (Epivir HBV)\r\n(Tablets): 150 mg (scored), 300 mg (generic), 100 mg (Epivir HBV)', '[Combivir and generic] Lamivudine 150 mg + Zidovudine 300 mg\r\n[Epzicom] Abacavir 600 mg + Lamivudine 300 mg\r\n[Trizivir] Abacavir 300 mg + Lamivudine 150 mg + Zidovudine 300 mg\r\n[Triumeq] Abacavir 600 mg + Dolutegravir 50 mg + Lamivudine 300 mg', '', 'aged under 4 weeks: 2 mg/kg twice daily\r\naged 4 weeks or over: 4 mg/kg (up to 150 mg) twice daily\r\n\r\nweight 14 kg to under 20 kg: 150 mg (1 tablet)\r\nweight 20 kg to under 25 kg: 225 mg (1 and half tablets)\r\nweight 25 kg or over: 300 mg (2 tablets)', '4 mg/kg (up to 150 mg) twice daily\r\n\r\nweight 14 kg to under 20 kg: 150 mg (1 tablet)\r\nweight 20 kg to under 25 kg: 225 mg (1 and half tablets)\r\nweight 25 kg or over: 300 mg (2 tablets)', '4 mg/kg (up to 150 mg) twice daily\r\n\r\nweight 14 kg to under 20 kg: 150 mg (1 tablet)\r\nweight 20 kg to under 25 kg: 225 mg (1 and half tablets)\r\nweight 25 kg or over: 300 mg (2 tablets)', '\r\nweight under 25 kg: 4 mg/kg (up to 150 mg) twice daily\r\nweight 25 kg or over: 150 mg twice daily or 300 mg once daily\r\n[Combivir and Generic] weight 30 kg or over: one tablet twice daily\r\n[Trizivir and Generic] one tablet twice daily \r\nif weight 40 kg or above\r\n[Epzicom] one tablet once daily\r\nif weight 25 kg or above\r\n[Triumeq] one tablet once daily\r\nif weight 40 kg or above', 'weight under 25 kg: 4 mg/kg (up to 150 mg) twice daily\r\nweight 25 kg or over: 150 mg twice daily or 300 mg once daily\r\n[Combivir and Generic] one tablet twice daily\r\n[Trizivir and Generic] one tablet twice daily\r\n[Epzicom] one tablet once daily\r\n[Triumeq]  one tablet once daily', 'Store lamivudine oral solution at room temperature. Screen patients with hepititus B virus (HBV) before administering lamivudine.'),
('a5', 'Stavudine (d4T, Zerit)', 'Stavudine', 'NRTI (rare)','(Oral Solution): 1 mg/mL','(Capsules): 15 mg, 20 mg, 30 mg, 40 mg', '(Oral Solution): 1 mg/mL\r\n(Capsules): 15 mg, 20 mg, 30 mg, 40 mg', '', '', 'birth to 13 days old: 0.5 mg/kg per dose twice daily 14 days old and over and weight under 30 kg: 1 mg/kg per dose twice daily', 'weight under 30 kg: 1 mg/kg per dose twice daily', 'weight under 30 kg: 1 mg/kg per dose twice daily', 'weight under 30 kg: 1 mg/kg per dose twice daily\r\nweight 30 kg or over: 30 mg per dose twice daily', 'weight under 30 kg: 1 mg/kg per dose twice daily\r\nweight 30 kg or over: 30 mg per dose twice daily', 'Shake stavudine oral solution well before use. Keep refrigerated; the solution \r\nis stable for 30 days.'),
('a6', 'Tenofovir Alafenamide (TAF)', 'Alafenamide', '', '','','', '[Descovy] Emtricitabine 200 mg + Tenofovir Alafenamide (TAF) 25 mg\r\n[Genvoya] Elvitegravir 150 mg + Cobicistat 150 mg + Emtricitabine 200 mg + TAF 10 mg\r\n[Odefsey] Emtricitabine 200 mg + Rilpivirine 25 mg + TAF 25 mg', '', '', '', '', '[Descovy] above 35 kg: one tablet once daily\r\n[Odefsey] 35 kg or above: one tablet once a day with a meal with at least 500 \r\ncalories. The meal is initial therapy in those with no ARV treatment history with \r\nHIV-1 RNA less or equal to 100,000 copies per mL; or to replace a stable ARV \r\nregimen in those who are viologically surpressed for at least 6 months with no \r\nhisotry of treatment failure and no known substitutions associated with \r\nresistance to the individual components of Odefesey.\r\n[Genvoya] 35 kg or above and aged at least 12 years: one tablet once a day with \r\nfood in ARV treatment-naive patients or to replace the current ARV regimen in \r\nthose who are virologically suppressed (HIV-1 RNA under 50 copies/mL) on \r\na stable ARV regimen for at least 6 months with no history of treatment failure and \r\nno known substitutions associated with resistance to the individual components \r\nof Genvoya.', '[Descovy] one tablet once daily\r\n[Odefsey] 35 kg or above: one tablet once a day with a meal with at least 500 \r\ncalories. The meal is initial therapy in those with no ARV treatment history with \r\nHIV-1 RNA less or equal to 100,000 copies per mL; or to replace a stable ARV \r\nregimen in those who are viologically surpressed for at least 6 months with no \r\nhisotry of treatment failure and no known substitutions associated with \r\nresistance to the individual components of Odefesey.\r\n[Genvoya] 35 kg or above and aged at least 12 years: one tablet once a day with \r\nfood in ARV treatment-naive patients or to replace the current ARV regimen in \r\nthose who are virologically suppressed (HIV-1 RNA under 50 copies/mL) on \r\na stable ARV regimen for at least 6 months with no history of treatment failure and \r\nno known substitutions associated with resistance to the individual components \r\nof Genvoya.', 'Measure serum creatinine before starting a TAF containing regimen.\r\nScreen patients for hepititus B virus (HBV) infection before use of TAF.\r\nSevere acute exacerbation of HBV infection can occur when TAF is \r\ndiscontinued; therefore, in patients with HBV infection monitor hepatic \r\nfunction for several months after therapy with TAF is stopped.\r\nIf using [Genvoya], please see the elvitegravir, emtricitabine, and \r\ncobicistat sections of the drug appendix for addition information. Use of \r\n[Genvoya] is not recommended with other ARV drugs. Do not use \r\n[Genvoya] with elvitegravir, cobicistat, tonofovir disproxil fumarate, \r\nemtricitabine, lamivudine, or protease inhibitors co-formulated with \r\ncobicistat. When using [Odefsey], refer to the rilpivirine section. Patients \r\nmust be able to take rilpivirine with a meal of at least 500 calories on a \r\nregular schedule'),
('a7', 'Tenofovir Disoproxil Fumarate (TDF, Viread)', 'Disoproxil', 'NRTI', '(Oral Powder): 40 mg per 1 g of oral powder','(Tablets): 150 mg, 200 mg, 250 mg, 300 mg','(Oral Powder): 40 mg per 1 g of oral powder\r\n(Tablets): 150 mg, 200 mg, 250 mg, 300 mg', '[Truvada low strength tablet]\r\nEmtricitabine 100 mg + Tenofovir Disoproxil Fumarate (TDF) 150 mg\r\nEmtricitabine 133 mg + TDF 200 mg\r\nEmtricitabine 167 mg + TDF 250 mg\r\n[Truvada tablet] Emtricitabine 200 mg + TDF 300 mg\r\n[Atripla] Efavirenz 600 mg + Emtricitabine 200 mg + TDF 300 mg\r\n[Complera] Emtricitabine 200 mg + Rilpivirine 25 mg + TDF 300 mg\r\n[Stribild] Elvitegravir 150 mg + Cobicistat 150 mg + Emtricitabine 200 mg + TDF 300 mg', '', 'not approved', 'not approved', 'not approved for ages below 2 years\r\n8 mg/kg/dose once daily \r\n[Truvada tablet]\r\n17 kg to below 22 kg: 100 mg FTC / 150 mg TDF tablet once daily\r\n22 kg to below 28 kg: 133 mg FTC / 200 mg TDF tablet once daily\r\n28 kg to below 35 kg: 167 mg FTC / 250 mg TDF tablet once daily', 'below 35 kg: 8 mg/kg/dose once daily\r\n35 kg and above: TDF 300 mg once daily\r\n[Truvada tablet]\r\n22 kg to below 28 kg: 133 mg FTC / 200 mg TDF tablet once daily\r\n28 kg to below 35 kg: 167 mg FTC / 250 mg TDF tablet once daily\r\n35 kg and above: 200 mg FTC / 300 mg TDF tablet once daily\r\n[Atripla] aged 12 or over and above 40 kg: one tablet once daily without food\r\n[Complera] above 35 kg: one tablet once daily with a meal of at least\r\n500 calories. Patients must be treatment-naive with baseline plasma RNA \r\nunder 100,000 copies/mL or virologically surpressed patients with no \r\nhistory of virologic failure, resistance to rilpivirine and other ARV drugs, and \r\nwho are currently on their first or second regimen.\r\n[Stribild] weight over 35 kg and Tanner stage 4 or 5: one tablet once a day in \r\ntreatment-naive or virologically surpressed adults with a meal.', 'TDF 300 mg once daily\r\n[Truvada tablet]\r\n28 kg to below 35 kg: 167 mg FTC / 250 mg TDF tablet once daily\r\n35 kg and above: 200 mg FTC / 300 mg TDF tablet once daily\r\n[Atripla] above 40 kg: one tablet once daily without food\r\n[Complera] above 35 kg: one tablet once daily with a meal of at least\r\n500 calories. Patients must be treatment-naive with baseline plasma RNA \r\nunder 100,000 copies/mL or virologically surpressed patients with no \r\nhistory of virologic failure, resistance to rilpivirine and other ARV drugs, and \r\nwho are currently on their first or second regimen.\r\n[Stribild] one tablet once a day in treatment-naive or virologically \r\nsurpressed adults with a meal.', 'Do not crush tablets. Measure serum creatinine and urine dipstick for protein and \r\nglucose before starting a TDF containing regimen. Screen patients for hepititus B \r\nvirus (HBV). In patients with HBV, monitor hepatic function for several months after \r\ntherapy with TDF is stopped. If using [Stribild], see the elvitegravir and cobicistat \r\nsections of the drug appendix for additional information.'),
('a8', 'Zidovudine (ZDV, AZT, Retrovir)', 'Zidovudine', 'NRTI','(Pediatric Oral Solution): 10 mg/mL (Syrup)(IV Infusion): 10 mg/mL','(Tablets): 300 mg (Capsules): 100 mg (IV Infusion): 10 mg/mL', '(Pediatric Oral Solution): 10 mg/mL (Syrup)\r\n(Tablets): 300 mg\r\n(Capsules): 100 mg\r\n(IV Infusion): 10 mg/mL', '[Combivir and generic] Lamivudine 150 mg + Zidovudine 300 mg\r\n[Trizivir] Abacavir 300 mg + Lamivudine 150 mg + Zidovudine 300 mg', '', 'Gestational Age 35 weeks or over:\r\nBirth to age 4 weeks: 4 mg/kg orally twice daily\r\nAged over 4 weeks: 12 mg/kg orally twice daily\r\nGestational Age 30 weeks to under 35 weeks:\r\nBirth to age 2 weeks: 2mg/kg orally twice daily\r\nAged 2 weeks to 6 to 8 weeks: 3 mg/kg orally twice daily\r\nAged over 6 to 8 weeks: 12 mg/kg orally twice daily\r\nGestational Age under 30 weeks:\r\nBirth to age 4 weeks: 2 mg/kg orally twice daily\r\nAged 4 weeks to 8 to 10 weeks: 3 mg/kg orally twice daily\r\nAged over 8 weeks to 10 weeks: 12 mg/kg orally twice daily\r\nBSA Dosing\r\n(Oral) 180-240 mg/m^2 BSA every 12 hours', 'weight 4 kg to under 9 kg: 12 mg/kg\r\nweight 9 kg to below 30 kg: 9 mg/kg\r\nweight 30 kg or over: 300 mg\r\nBSA Dosing\r\n(Oral) 180-240 mg/m^2 BSA every 12 hours', 'weight 9 kg to below 30 kg: 9 mg/kg\r\nweight 30 kg or over: 300 mg\r\nBSA Dosing\r\n(Oral) 180-240 mg/m^2 BSA every 12 hours', '[Combivir and Generic] weight 30 kg or over: one tablet twice daily\r\n[Trizivir] one tablet twice daily if weight 40 kg or above\r\nBSA Dosing\r\n(Oral) 180-240 mg/m^2 BSA every 12 hours', '300 mg twice daily\r\n[Combivir and Generic] one tablet twice daily\r\n[Trizivir] one tablet twice daily', 'For infants unable to tolerate oral agents, the IV dose should be 75% of the oral \r\ndose with the same dosing interval.'),
('a9', 'Dolutegravir (DTG, Tivicay)', 'Dolutegravir', '', '','(Tablets): 10 mg, 25 mg, 50 mg','(Tablets): 10 mg, 25 mg, 50 mg', '[Triumeq] Abacavir 600 mg plus dolutegravir 50 mg plus lamivudine 300 mg', '', 'Not approved.', 'Not approved.', 'Not FDA approved for use in children\r\nweighing <30 kg.\r\n\r\nChildren Weighing ?30 to <40 kg:\r\n30kg to <40kg: 50mg once daily (one tablet)\r\n>40kg: 10mg + 25mg once daily (two tablets)\r\n', 'Children and Adolescents (Weighing ?40 kg):\r\nTreatment-naive or treatment-experienced/(INSTI)-naive: 50mg once daily\r\nTreatment-naive or treatment-experienced/INSTI-naive when co-administratered\r\nwith the following potent UGT1A/CYP3A inducers: efavirenz, fosamprenavir/ritonavir,\r\ntipranavir/ritonavir, or rifampin: 50mg twice daily\r\nINSTI-experienced with any INSTI-associated resistance substitutions or clincally \r\nsuspected INSTI resistance: 50mg twice daily\r\n\r\n[Triumeq] Abacavir plus Dolutegravir plus\r\nLamivudine:\r\n1 tablet once daily\r\nFor use in patients who are ARV treatmentnaive\r\nor treatment-experienced (but\r\nINSTI-naive) and not being treated with\r\nUGT1A1/CYP3A inducers\r\n', 'Treatment-naive or treatment-experienced/(INSTI)-naive: 50mg once daily\r\nTreatment-naive or treatment-experienced/INSTI-naive when co-administratered\r\nwith the following potent UGT1A/CYP3A inducers: efavirenz, fosamprenavir/ritonavir,\r\ntipranavir/ritonavir, or rifampin: 50mg twice daily\r\nINSTI-experienced with any INSTI-associated resistance substitutions or clincally \r\nsuspected INSTI resistance: 50mg twice daily\r\n\r\n[Triumeq] Abacavir plus Dolutegravir plus\r\nLamivudine:\r\n1 tablet once daily\r\nFor use in patients who are ARV treatmentnaive\r\nor treatment-experienced (but\r\nINSTI-naive) and not being treated with\r\nUGT1A1/CYP3A inducers', ''),
('a10', 'Etravirine (ETR, Intelence, TMC 125)', 'Etravirine', '', '','(Tablets): 25 mg, 100 mg, 200 mg','(Tablets): 25 mg, 100 mg, 200 mg', '', '', 'not approved', 'not approved', 'not approved', 'Dose based on body weight:\r\n16 kg to below 20 kg: 100 mg twice daily\r\n20 kg to below 25 kg: 125 mg twice daily\r\n25 kg to below 30 kg: 150 mg twice daily\r\n30 kg and over: 200 mg twice daily', '200 mg twice daily following a meal', 'Always administer etravirine following a meal. Store tablets at room temperature. \r\nPatients unable to swallow tablets may disperse tablets in liquid.'),
('a12', 'Rilpivirine (RPV, Edurant)', 'Rilpivirine', '', '','(Tablets): 25 mg','(Tablets): 25 mg', '[Complera] Emtricitabine 200 mg + Rilpivirine 25 mg + TDF 300 mg\r\n[Odefsey] Emtricitabine 200 mg + Rilpivirine 25 mg + TAF 25 mg', '', 'not approved', 'not approved', 'not approved', 'not approved for children below 12 years.\r\naged 12 years and over and weight 35 kg and above: 25 mg once daily\r\n[Complera] above 35 kg: one tablet once daily with a meal of at least\r\n500 calories. Patients must be treatment-naive with baseline plasma RNA \r\nunder 100,000 copies/mL or virologically surpressed patients with no \r\nhistory of virologic failure, resistance to rilpivirine and other ARV drugs, and \r\nwho are currently on their first or second regimen.\r\n[Odefsey] 35 kg or above: one tablet once a day with a meal with at least 500 \r\ncalories. The meal is initial therapy in those with no ARV treatment history with \r\nHIV-1 RNA less or equal to 100,000 copies per mL; or to replace a stable ARV \r\nregimen in those who are viologically surpressed for at least 6 months with no \r\nhisotry of treatment failure and no known substitutions associated with \r\nresistance to the individual components of Odefesey.', '25 mg once daily\r\n[Complera] above 35 kg: one tablet once daily with a meal of at least\r\n500 calories. Patients must be treatment-naive with baseline plasma RNA \r\nunder 100,000 copies/mL or virologically surpressed patients with no \r\nhistory of virologic failure, resistance to rilpivirine and other ARV drugs, and \r\nwho are currently on their first or second regimen.\r\n[Odefsey] 35 kg or above: one tablet once a day with a meal with at least 500 \r\ncalories. The meal is initial therapy in those with no ARV treatment history with \r\nHIV-1 RNA less or equal to 100,000 copies per mL; or to replace a stable ARV \r\nregimen in those who are viologically surpressed for at least 6 months with no \r\nhisotry of treatment failure and no known substitutions associated with \r\nresistance to the individual components of Odefesey.', 'Patients must be able to take rilpivirine with a meal of at least 500 calories on a \r\nregular schedule. Do not use rilpivirine with other non-nucleoside reverse \r\ntranscriptase inhibitors or with proton pump inhibitors. Antacids should only be \r\ntaken either at least 2 hours before or 4 hour after rilpivirine. Do not start rilpivirine \r\nin patients with HIV RNA>100,000 copies/mL.'),
('a14', 'Darunavir (DRV, Prezista)', 'Darunavir', '','(Oral Suspension): 100 mg/mL','(Tablets): 75 mg, 150 mg, 400 mg, 600 mg, 800 mg', '(Oral Suspension): 100 mg/mL\r\n(Tablets): 75 mg, 150 mg, 400 mg, 600 mg, 800 mg', '[Prezcobix] Darunavir 800 mg + Cobicistat 150 mg', '', 'not approved', 'not approved', 'age below 3 years: Do not use darunavir if weight below 10 kg or age below 3\r\nage 3 years and above who are treatment-naive and treatment-\r\nexperienced with or without one or more darunavir resistance-\r\nassociated mutations. All doses are twice daily with food:\r\nweight 10 kg to below 11 kg: darunavir 200 mg (2.0 mL) + ritonavir 32 mg (0.4 mL)\r\nweight 11 kg to below 12 kg: darunavir 220 mg (2.2 mL) + ritonavir 32 mg (0.4 mL)\r\nweight 12 kg to below 13 kg: darunavir 240 mg (2.4 mL) + ritonavir 40 mg (0.5 mL)\r\nweight 13 kg to below 14 kg: darunavir 260 mg (2.6 mL) + ritonavir 40 mg (0.5 mL)\r\nweight 14 kg to below 15 kg: darunavir 280 mg (2.8 mL) + ritonavir 48 mg (0.6 mL)\r\nweight 15 kg to below 30 kg: darunavir 375 mg (tablets or 3.8 mL) + ritonavir 48 mg (0.6 mL)\r\nweight 30 kg to below 40 kg: darunavir 450 mg (tablets or 4.6 mL) + ritonavir 100 mg (tablet or 1.25 mL)\r\nweight 40 kg and over: darunavir 600 mg (tablet or 6 mL) + ritonavir 100 mg (tablet or 1.25 mL)\r\n', 'age 6 to below 12 years who are treatment-naive and treatment-\r\nexperienced with or without one or more darunavir resistance-\r\nassociated mutations. All doses are twice daily with food:\r\nweight 10 kg to below 11 kg: darunavir 200 mg (2.0 mL) + ritonavir 32 mg (0.4 mL)\r\nweight 11 kg to below 12 kg: darunavir 220 mg (2.2 mL) + ritonavir 32 mg (0.4 mL)\r\nweight 12 kg to below 13 kg: darunavir 240 mg (2.4 mL) + ritonavir 40 mg (0.5 mL)\r\nweight 13 kg to below 14 kg: darunavir 260 mg (2.6 mL) + ritonavir 40 mg (0.5 mL)\r\nweight 14 kg to below 15 kg: darunavir 280 mg (2.8 mL) + ritonavir 48 mg (0.6 mL)\r\nweight 15 kg to below 30 kg: darunavir 375 mg (tablets or 3.8 mL) + ritonavir 48 mg (0.6 mL)\r\nweight 30 kg to below 40 kg: darunavir 450 mg (tablets or 4.6 mL) + ritonavir 100 mg (tablet or 1.25 mL)\r\nweight 40 kg and over: darunavir 600 mg (tablet or 6 mL) + ritonavir 100 mg (tablet or 1.25 mL)\r\nfor ages 12 and above (treatment-naive or treatment-experienced with no darunavir \r\nresistance-associated mutations):\r\nweight 30 kg to below 40 kg: darunavir 675 mg (combination of tablets) + ritonavir 100 mg once daily\r\nweight 40 kg and above: darunavir 800 mg (tablet or combination of tablets) + ritonavir 100 mg once daily\r\nAge 12 and up weighing at least 40 kg (Treatment-experienced with at least one darunavir \r\nresistance-associated mutation):\r\nDarunavir 600 mg + Ritonavir 100 mg both twice daily with food\r\nThe use of cobicistat is not recommended with darunavir 600 mg twice daily', 'treatment-naive or treatment-experienced with no darunavir resistance-\r\nassociated mutations:\r\nDarunavir 800 mg (tablet) + Cobicistat 150 mg (tablet) or [Prezcobix] once daily\r\nwith food', 'Boosting darunavir with cobicistat is currently not recommended in children aged \r\nunder 18 years.\r\n\r\nIn patients with one or more darunavir-associated mutation(s), darunavir should only \r\nbe used twice daily. Darunavir resistance-associated mutations are: V11I, V32I, \r\nL33F, I47V, I50V, I54L, I54M, T74P, L76V, I84V, and L89V. Darunavir must be \r\nadministered with food. Store darunavir at room temperature. Store oral suspension at \r\nroom temperature and shake well before dosing.'),
('a15', 'Fosamprenavir (FPV, Lexiva)', 'Fosamprenavir', '','(Oral Suspension): 50 mg/mL','(Tablets): 700 mg', '(Oral Suspension): 50 mg/mL\r\n(Tablets): 700 mg', '', '', 'not recommended', 'not recommended for infants younger than 6 months\r\nonce-daily dosing is not recommended for any pediatric patient.\r\nTwice-daily dosage regimens by weight for pediatric patients at least \r\n6 months old using Lexiva Oral Suspension with Ritonavir:\r\nweight under 11 kg: fosamprenavir 45 mg/kg/dose + ritonavir 7 mg/kg/dose\r\nweight 11 kg to under 15 kg: fosamprenavir 30 mg/kg/dose + ritonavir 3 mg/kg/dose\r\nweight 15 kg to below 20 kg: fosamprenavir 23 mg/kg/dose + ritonavir 3 mg/kg/dose\r\nweight 20 kg and above: fosamprenavir 23 mg/kg/dose + ritonavir 3 mg/kg/dose', 'once-daily dosing is not recommended for any pediatric patient.\r\nTwice-daily dosage regimens by weight for pediatric patients using Lexiva Oral Suspension \r\nwith Ritonavir:\r\nweight under 11 kg: fosamprenavir 45 mg/kg/dose + ritonavir 7 mg/kg/dose\r\nweight 11 kg to under 15 kg: fosamprenavir 30 mg/kg/dose + ritonavir 3 mg/kg/dose\r\nweight 15 kg to below 20 kg: fosamprenavir 23 mg/kg/dose + ritonavir 3 mg/kg/dose\r\nweight 20 kg and above: fosamprenavir 23 mg/kg/dose + ritonavir 3 mg/kg/dose', 'once-daily dosing is not recommended for any pediatric patient.\r\nTwice-daily dosage regimens by weight for pediatric patients using Lexiva Oral Suspension \r\nwith Ritonavir:\r\nweight under 11 kg: fosamprenavir 45 mg/kg/dose + ritonavir 7 mg/kg/dose\r\nweight 11 kg to under 15 kg: fosamprenavir 30 mg/kg/dose + ritonavir 3 mg/kg/dose\r\nweight 15 kg to below 20 kg: fosamprenavir 23 mg/kg/dose + ritonavir 3 mg/kg/dose\r\nweight 20 kg and above: fosamprenavir 23 mg/kg/dose + ritonavir 3 mg/kg/dose\r\nNote: forsamprenavir tablets + 100 mg ritonavir, both given twice daily, can be used on patients with \r\na weight of at least 39 kg. Ritonavir pills can be used on patients weighing at least 33 kg.\r\n\r\n', 'once-daily dosing is not recommended for any pediatric patient.\r\nARV-Naive Patients:\r\nTwice daily regimen: Fosamprenavir 700 mg + Ritonavir 100 mg both twice daily\r\nOnce daily regimen: Fosamprenavir 1400 mg + Ritonavir 100-200 mg, both once daily\r\nProtease Inhibitor (PI)-Experienced Patients:\r\nFosamprenavir 700 mg + Ritonavir 100 mg both twice daily \r\nNote: once daily administration is not recommended\r\nFosamprenavir in Combination with Efavirenz (Adult):\r\nOnly fosamprenavir boosted with ritonavir should be used in combination with \r\nefavirenz.\r\nTwice daily regimen: Fosamprenavir 700 mg + Ritonavir 100 mg both twice daily + \r\nEfavirenz 600 mg once daily\r\nPI-Naive Patients Only, Once daily regimen: Fosamprenavir 1400 mg + Ritonavir \r\n300 mg + Efavirenz 600 mg all once daily.', 'Fosamprenavir tablets with ritonavir should be taken with food. Children should take \r\nsuspension with food. Patients taking antacids or buffered formulations of \r\ndidanosine should take fosamprenavir at least 1 hour before or after antacid or \r\ndidanosine use. Fosamprenavir should be used with caution in patients with \r\nsulfonamide allergy. Shake oral suspension well before use. Refridgeration is not \r\nrequired.\r\n\r\nDosing patients with hepatic impairment: Dosage adjustment is recommended. \r\nRefer to the package insert.'),
('a16', 'Indinavir (IDV, Crixivan)', 'Indinavir', '', '','(Capsules): 100 mg, 200 mg, and 400 mg','(Capsules): 100 mg, 200 mg, and 400 mg', '', '', 'not approved', 'not approved', 'not approved', 'not approved for children.\r\nadolescent dose: 800 mg indinavir + 100 or 200 mg ritonavir every 12 hours', '800 mg indinavir + 100 or 200 mg ritonavir every 12 hours', 'When given in combination with ritonavir, meal restrictions are not necessary.\r\nAdequate hydration is required. If co-administered with didanosine, give indinavir \r\nand didanosine at least 1 hour apart on an empty stomache. Store indinavir capsules \r\nat room temperature.'),
('a17', 'Lopinavir/Ritonavir (LPV/r, Kaletra)', 'Lopinavir', '', '(Oral Solution): 80 mg/20 mg LPV/r per mL','(Film-coated tablets): 100 mg/25 mg LPV/r, 200 mg/50 mg LPV/r','(Oral Solution): 80 mg/20 mg LPV/r per mL\r\n(Film-coated tablets): 100 mg/25 mg LPV/r, 200 mg/50 mg LPV/r', '', '', 'Do not administer to neonates before a post-menstrual age of 42 weeks \r\nand a postnatal age of at least 14 days.\r\nDosing for individuals not receieving concomitant Nevirapine, \r\nEfavirenz, Fosamprenavir, or Nelfinavir\r\nInfants at least 14 days old: 300 mg/75 mg lopinavir/ritonavir per m^2 of BSA \r\ntwice daily. Once daily dosing is not recommended', 'Dosing for individuals not receieving concomitant Nevirapine, \r\nEfavirenz, Fosamprenavir, or Nelfinavir\r\n300 mg/75 mg lopinavir/ritonavir per m^2 of BSA twice daily. Once daily dosing is \r\nnot recommended', 'Dosing for individuals not receieving concomitant Nevirapine, \r\nEfavirenz, Fosamprenavir, or Nelfinavir:\r\nAge 12 months or below: 300 mg/75 mg lopinavir/ritonavir per m^2 of BSA twice daily. Once daily \r\ndosing is not recommended\r\nAge above 12 months: 300 mg/75 mg lopinavir/ritonavir per m^2 of BSA per dose twice daily. \r\n(Maximum dose 400 mg/100 mg lopinavir/ritonavir twice daily). This dose is the preferred dose for \r\ntreatment-experienced patients who could harbor virus with decreased lopinavir susceptibility.\r\n\r\n230 mg/57.5 mg lopinavir/ritonavir per m^2 of BSA per dose twice daily can be used on ARV-naive \r\npatients aged more than 1 year. This dose should not  be used in treatment-experienced patients \r\nwho could harbor virus with decreased lopinavir susceptibility.\r\n\r\nWeight-band dosing for 100 mg/25 mg Lopinavir/Ritonavir Pediatric Tablets for Children/\r\nAdolescents:\r\nDosing is based on body weight and are given the following amounts of 300 mg/m^2/dose \r\ntwice daily and 230 mg/m^2/dose twice daily respectively:\r\nweight 15 kg to 20 kg: 2 and 2\r\nweight above 20 kg to 25 kg: 3 and 2\r\nweight above 25 kg to 30 kg: 3 and 3\r\nweight above 30 kg to 35 kg: 4 and 3\r\nweight above 35 kg to 45 kg: 4 and 4\r\nweight above 45 kg: (4 or 5) and 4', 'Dosing for individuals not receieving concomitant Nevirapine, \r\nEfavirenz, Fosamprenavir, or Nelfinavir:\r\n300 mg/75 mg lopinavir/ritonavir per m^2 of BSA per dose twice daily. \r\n(Maximum dose 400 mg/100 mg lopinavir/ritonavir twice daily). This dose is the preferred dose for \r\ntreatment-experienced patients who could harbor virus with decreased lopinavir susceptibility.\r\n\r\n230 mg/57.5 mg lopinavir/ritonavir per m^2 of BSA per dose twice daily can be used on ARV-naive \r\npatients aged more than 1 year. This dose should not  be used in treatment-experienced patients \r\nwho could harbor virus with decreased lopinavir susceptibility.\r\n\r\nWeight-band dosing for 100 mg/25 mg Lopinavir/Ritonavir Pediatric Tablets for Children/\r\nAdolescents:\r\nDosing is based on body weight and are given the following amounts of 300 mg/m^2/dose \r\ntwice daily and 230 mg/m^2/dose twice daily respectively:\r\nweight 15 kg to 20 kg: 2 and 2\r\nweight above 20 kg to 25 kg: 3 and 2\r\nweight above 25 kg to 30 kg: 3 and 3\r\nweight above 30 kg to 35 kg: 4 and 3\r\nweight above 35 kg to 45 kg: 4 and 4\r\nweight above 45 kg: (4 or 5) and 4', '800 mg/200 mg lopinavir/ritonavir once daily\r\nor\r\n400 mg/100 mg lopinavir/ritonavir twice daily\r\nDo not use once-daily dosing on children or adolescents, or in patients receiving \r\nconcomitant therapy with nevirapine, efavirenz, fosamprenavir, or nelfinavir, or in \r\npatients with three or more lopinavir-associated mutations.', 'Lopinavir/ritonavir tablets must be swallowed whole, do not crush or split tablets.\r\nLopinavir/ritonavir oral solution should be administered with a high fat meal. The \r\noral soliution can be kept at room temperature if used within 2 months.\r\n\r\nUse of lopinavir/ritonavir once daily is specifically contraindicated if three or more of\r\nthe following lopinavir-associated substitutions are present: L10F/I/R/V, \r\nK20M/N/R, L24I, L33F, M36I, I47V, G48V, I54L/T/V, V82A/C/F/S/T, and I84V. \r\n-because higher lopinavir trough concentrations may be required to suppress \r\nresistant virus.\r\n'),
('a18', 'Nelfinavir (NFV, Viracept)', 'Nelfinavir', '','','(Tablets): 250 mg and 625 mg', '(Tablets): 250 mg and 625 mg', '', '', 'not approved', 'not approved', 'not approved for ages below 2 years.\r\nages 2 and above: 45-55 mg/kg twice daily', 'ages 13 and below: 45-55 mg/kg twice daily\r\nages above 13: 1250 mg (five 250 mg tablets or two 625 mg tablets) twice daily\r\nSome adolescents require higher doses than adults to achieve equivalent drug exposures. Consider \r\nusing therapeutic drug monitoring to guide appropriate dosing.', '1250 mg (five 250 mg tablets or two 625 mg tablets) twice daily\r\nSome adolescents require higher doses than adults to achieve equivalent drug \r\nexposures. Consider using therapeutic drug monitoring to guide appropriate dosing.', 'Administer nelfinavir with a meal or light snack. If co-administered with didanosine, \r\nadminister nelfinavir 2 hours before or 1 hour after didanosine. Patients unable to \r\nswallow nelfinavir tablets can dissolve them in a small amount of water. After \r\nconsumption, the glass should be rinsed and swallowed, to ensure the entire dose \r\nis consumed. Tablets can also be crushed and administered with nonacidic foods.'),
('a19', 'Saquinavir (SQV, Invirase)', 'Saquinavir', '','','(Capsules): 200 mg (Tablets): 500 mg', '(Capsules): 200 mg\r\n(Tablets): 500 mg', '', '', 'Not approved.', 'Not approved.', 'Pediatric Dose:\r\nNot approved for use in children and\r\nadolescents aged <16 years.\r\n\r\nInvestigational Doses in Treatment-Experienced Children:\r\nSaquinavir must be boosted with ritonavir.\r\nAged <2 Years:\r\nNo dose has been determined.\r\n\r\nAged ?2 Years (Conditional Dosing Based on Limited Data):\r\n5kg to <15kg: saquinavir 50 mg/kg plus ritonavir 3 mg/kg, both twice daily\r\n15kg to 40kg: saquinavir 50 mg/kg plus ritonavir 2.5 mg/kg, both twice daily\r\n>=40kg: saquinavir 50 mg/kg plus ritonavir 100 mg, both twice daily\r\n', 'Investigational Doses in Treatment-Experienced Children:\r\nSaquinavir must be boosted with ritonavir.\r\nAged ?2 Years (Conditional Dosing Based on Limited Data):\r\n>=40kg: saquinavir 50 mg/kg plus ritonavir 100 mg, both twice daily\r\n\r\nAdolescent (Aged ?16 years):\r\nSaquinavir should only be used in combination with ritonavir.\r\nSaquinavir 1000 mg plus ritonavir 100 mg, both twice daily.\r\n\r\nCobicistat is not interchangeable with ritonavir to\r\nincrease systemic exposure of saquinavir.\r\nSaquinavir is not recommended for use in\r\ncombination with cobicistat.', 'Saquinavir should only be used in combination with ritonavir.\r\nSaquinavir 1000 mg plus ritonavir 100 mg, both twice daily.\r\n\r\nCobicistat is not interchangeable with ritonavir to\r\nincrease systemic exposure of saquinavir.\r\nSaquinavir is not recommended for use in\r\ncombination with cobicistat.', ''),
('a20', 'Tipranavir (TPV, APTIVUS)', 'Tipranavir', '','(Oral Solution): 100 mg tipranavir/mL, with 116 International Units (IU) vitamin E/mL','(Capsules): 250 mg', '(Oral Solution): 100 mg tipranavir/mL, with 116 International Units (IU) vitamin E/mL\r\n(Capsules): 250 mg', '', '', 'Not approved.', 'Not approved.', 'Not approved for use in children aged <2 years.\r\n\r\nPediatric Dose (Aged 2–18 Years):\r\nNote: Not recommended for treatment-naive\r\npatients\r\nBody Surface Area Dosing:\r\nTipranavir 375 mg/m2 plus ritonavir 150\r\nmg/m2, both twice daily (maximum tipranavir\r\n500 mg plus ritonavir 200 mg, both twice\r\ndaily)\r\nWeight-Based Dosing:\r\nTipranavir 14 mg/kg plus ritonavir 6 mg/kg,\r\nboth twice daily (maximum tipranavir 500 mg\r\nplus ritonavir 200 mg, both twice daily)\r\n', 'Pediatric Dose (Aged 2–18 Years):\r\nNote: Not recommended for treatment-naive\r\npatients\r\nBody Surface Area Dosing:\r\nTipranavir 375 mg/m2 plus ritonavir 150\r\nmg/m2, both twice daily (maximum tipranavir\r\n500 mg plus ritonavir 200 mg, both twice\r\ndaily)\r\nWeight-Based Dosing:\r\nTipranavir 14 mg/kg plus ritonavir 6 mg/kg,\r\nboth twice daily (maximum tipranavir 500 mg\r\nplus ritonavir 200 mg, both twice daily)', 'Note: Not recommended for treatment-naive\r\npatients.\r\nTipranavir 500 mg (two 250-mg capsules)\r\nplus ritonavir 200 mg, both twice daily', ''),
('a21', 'Enfuvirtide (T-20, Fuzeon)', 'Enfuvirtide', '', '(Lyophilized Powder for Injection): 108-mg vial of enfuvirtide. Reconstitution with 1.1 mL sterile water will deliver 90 mg/mL. (Convenience Kit): 60 single-use vials of enfuvirtide (108-mg vial reconstituted as 90 mg/mL, 60 vials of sterile water for injection, 60 reconstitution syringes (3 mL), 60 administration syringes (1 mL), alcohol wipes)','(Lyophilized Powder for Injection): 108-mg vial of enfuvirtide. Reconstitution with 1.1 mL sterile water will deliver 90 mg/mL. (Convenience Kit): 60 single-use vials of enfuvirtide (108-mg vial reconstituted as 90 mg/mL, 60 vials of sterile water for injection, 60 reconstitution syringes (3 mL), 60 administration syringes (1 mL), alcohol wipes)','(Lyophilized Powder for Injection): 108-mg vial of enfuvirtide. Reconstitution with 1.1 mL \r\nsterile water will deliver 90 mg/mL.\r\n\r\n(Convenience Kit): 60 single-use vials of enfuvirtide (108-mg vial reconstituted as 90 \r\nmg/mL, 60 vials of sterile water for injection, 60 reconstitution syringes (3 mL), 60 \r\nadministration syringes (1 mL), alcohol wipes)', '', '', 'Not approved.', 'Not approved.', 'Not approved.', '2 mg/kg (maximum dose 90 mg [1 mL])\r\ntwice daily injected subcutaneously (SQ) into\r\nthe upper arm, anterior thigh, or abdomen\r\n\r\nAdolescents (Aged >16 Years):\r\n90 mg (1 mL) twice daily injected SQ into the\r\nupper arm, anterior thigh, or abdomen', '90 mg (1 mL) twice daily injected SQ into the\r\nupper arm, anterior thigh, or abdomen', ''),
('a22', 'Maraviroc (MVC, Selzentry)', 'Maraviroc', '', '','(Tablets): 150 mg and 300 mg','(Tablets): 150 mg and 300 mg', '', '', 'Not approved.', 'Not approved.', 'Not approved.', 'Not approved.', 'When given with potent CYP3A inhibitors (with or without CYP3A inducers)\r\nincluding protease inhibitors (except tipranavir/ritonavir [TPV/r]) and\r\nelvitegravir/ritonavir: 150mg twice daily\r\n\r\nWhen given with nucleoside reversetranscriptase inhibitors, enfuvirtide,\r\nTPV/r, nevirapine, raltegravir, and drugs that are not potent CYP3A inhibitors \r\nor inducers: 300mg twice daily\r\n\r\nWhen given with potent CYP3A inducers including efavirenz and etravirine\r\n(without a potent CYP3A inhibitor): 600mg twice daily\r\n', ''),
('a23', 'Elvitegravir (EVG, VITEKTA)', 'Elvitegravir', '', '','(Tablets): 85 mg and 150 mg','(Tablets): 85 mg and 150 mg', '[Stribild] Elvitegravir 150 mg plus cobicistat 150 mg plus emtricitabine 200 mg plus tenofovir disoproxil\r\n(TDF) 300 mg\r\n[Genvoya] Elvitegravir 150 mg plus cobicistat 150 mg plus emtricitabine 200 mg plus tenofovir\r\nalafenamide (TAF) 10 mg', '', 'No data on appropriate dose of elvitegravir as\r\nVitekta or in Stribild or Genvoya in children\r\nwith body weight <35 kg.', 'No data on appropriate dose of elvitegravir as\r\nVitekta or in Stribild or Genvoya in children\r\nwith body weight <35 kg.', 'No data on appropriate dose of elvitegravir as\r\nVitekta or in Stribild or Genvoya in children\r\nwith body weight <35 kg.', 'Genvoya (Any Sexual Maturity Rating; Tanner\r\nStage):\r\nOne tablet once daily\r\n\r\nStribild (SMR 4 or 5):\r\nOne tablet once daily\r\nElvitegravir (as Vitekta) in combination with\r\nan HIV PI co-administered with ritonavir and\r\nanother antiretroviral (ARV) drug.', 'Genvoya (Any Sexual Maturity Rating; Tanner\r\nStage):\r\nOne tablet once daily\r\n\r\nStribild (SMR 4 or 5):\r\nOne tablet once daily\r\nElvitegravir (as Vitekta) in combination with\r\nan HIV PI co-administered with ritonavir and\r\nanother antiretroviral (ARV) drug.', ''),
('a11', 'Nevirapine (NVP, Viramune)', 'Nevirapine', '', '(suspension): 10 mg/mL','(immediate-release tablets): 200 mg (extended-release (XR) tablets): 100 mg, 400 mg','(immediate-release tablets): 200 mg\r\n(extended-release (XR) tablets): 100 mg, 400 mg\r\n(suspension): 10 mg/mL', '', 'Pediatric Dose: Immediate Release and Suspension Formulations:\r\ngestational age below 1 month: Investigational dose not Food and Drug \r\nAdministration approved\r\n34-37 weeks gestational age(no lead in): 4 mg/kg/dose twice daily for the \r\nfirst week increasing to 6 mg/kg twice daily thereafter\r\n37 weeks gestational age below 1 month: 6 mg/kg/dose twice daily (no \r\nlead in)\r\n', 'refer to HIV treatment if below 1 month age.\r\n\r\nage 1 month and over: 200 mg/m^2 of BSA/dose twice daily after lead-in \r\ndosing. In children aged 2 years and below some experts initiate nevirapine \r\nwithout a lead-in. (max dose of immediate release tablets is 200 mg twice \r\ndaily.', '200 mg/m^2 of BSA/dose twice daily after lead-in dosing. In children aged \r\n2 years and below some experts initiate nevirapine without a lead-in. (max \r\ndose of immediate release tablets is 200 mg twice daily.', '200 mg/m^2 of BSA/dose twice daily after lead-in dosing. In children aged \r\n2 years and below some experts initiate nevirapine without a lead-in. (max \r\ndose of immediate release tablets is 200 mg twice daily.', 'below 8 years:\r\n200 mg/m^2 of BSA/dose twice daily after lead-in dosing. In children aged \r\n2 years and below some experts initiate nevirapine without a lead-in. (max \r\ndose of immediate release tablets is 200 mg twice daily.\r\n8 years old and above:\r\n120-150 mg/m^2 BSA/dose twice daily after lead-in dosing. (Max dose of \r\nimmediate release tablets is 200 mg twice daily.)\r\nfor older adolescents: 200 mg twice daily or 400 mg extended release once \r\ndaily', '200 mg twice daily or 400 mg extended release once daily', 'Shake suspension well ebfore administering and store at room temperature.\r\nNevirapine-associated skin rash usually occurs within the first 6 weeks of therapy.\r\nIf rash occurs during the first 14 day lead-in, do not increase dose until rash resolves.\r\nNevirapine extended-release tablets must be swallowed whole.\r\n\r\nPatients 6 years and over who are already taking immediate release nevirapine \r\ntwice daily can be switched to nevirapine extended release without lead-in dosing.\r\nA higher dose of ritonavir-boosted lopinavir may be needed (see Ritonavir-Boosted \r\nLopinavir section).'),
('a24', 'Efavirenz (EFV, Sustiva)', 'Efavirenz', '', '','(Tablets): 600 mg (Capsules): 50 mg, 200 mg','(Tablets): 600 mg\r\n(Capsules): 50 mg, 200 mg', '[Atripla] Efavirenz 600 mg + Emtricitabine 200 mg + TDF 300 mg', '', 'not approved', 'not approved', 'for children aged 3 years or above and weighing 10 kg and above:\r\n10 kg to below 15 kg: 200 mg once daily\r\n15 kg to below 20 kg: 250 mg once daily\r\n20 kg to below 25 kg: 300 mg once daily\r\n25 kg to below 32.5 kg: 350 mg once daily\r\n32.5 kg to below 40 kg: 400 mg once daily\r\n40 kg and above: 600 mg once daily', 'weights 40 kg and above: 600 mg once daily\r\n[Atripla] above 40 kg: one tablet once daily without food', '600 mg once daily\r\none tablet daily\r\n[Atripla] above 40 kg: one tablet once daily without food', 'Can be swallowed whole as a capsule or tablet or but sprinkling the contents of an \r\nopened capsule on food. Administer whole capsule or tablet on an empty stomach. \r\nAvoid administration with a high fat meal. Bedtime dosing recommended. Use with \r\ncaution on female adolescents.'),
('a25', 'Raltegravir (RAL, Isentress)', 'Raltegravir', '','(Granules for Oral Suspension): Single-use packet of 100 mg','(Tablets): 400 mg (film-coated poloxamer tablet) (Chewable Tablets): 100 mg (scored) and 25 mg Note: Film-coated tablets, chewable tablets, and oral suspension are not interchangeable.', '(Tablets): 400 mg (film-coated poloxamer tablet)\r\n(Chewable Tablets): 100 mg (scored) and 25 mg\r\n(Granules for Oral Suspension): Single-use packet of 100 mg\r\n\r\nNote: Film-coated tablets, chewable tablets, and oral suspension are not interchangeable.', '', '', 'Not approved.', '[Oral Suspension Dosing Table]\r\nChildren Aged >= 4 weeks:\r\n3kg to <4kg: 1mL (20mg) twice daily\r\n4kg to <6kg: 1.5mL (30mg) twice daily\r\n6kg to <8kg: 2mL (40mg) twice daily\r\n8kg to <11kg: 3mL (60mg) twice daily\r\n11kg to <14kg: 4mL (80mg) twice daily\r\n14kg to <20kg:5mL(100mg) twice daily', 'Children Aged 2 to <12 Years:\r\n<25 kg: Chewable tablet twice daily\r\n(maximum of 300 mg twice daily). See table\r\nbelow for chewable tablet dose.\r\n?25 kg: 400-mg film-coated tablet twice daily\r\nor chewable tablets twice daily. See', 'Children Aged 2 to <12 Years:\r\n<25 kg: Chewable tablet twice daily\r\n(maximum of 300 mg twice daily). See table\r\nbelow for chewable tablet dose.\r\n?25 kg: 400-mg film-coated tablet twice daily\r\nor chewable tablets twice daily. See table\r\nbelow for chewable tablet dose.\r\n\r\n[Chewable Tablet Dosing Table]\r\n11kg to <14kg: 3 x 25mg twice daily\r\n14kg to <20kg: 1 x 100mg twice daily\r\n20kg to <28kg: 1.5 x 100mg twice daily\r\n28kg to <40kg: 2 x 100mg twice daily\r\n>=40kg: 3 x 100mg twice daily\r\n\r\n*The 100-mg chewable tablet can be divided into equal halves.\r\n\r\nChildren Aged >12 Years:\r\n400-mg film-coated tablet twice daily\r\n\r\n', '400-mg film-coated tablet twice daily', 'Avoid taking aluminum and/or magnesium\r\ncontaining antacids.\r\n\r\nChewable tablets and oral suspension have\r\nbetter bioavailability than the film-coated\r\ntablets. Because the formulations are not\r\ninterchangeable, do not substitute chewable\r\ntablets or oral suspension for film-coated\r\ntablets. See specific recommendations for\r\nproper dosing of different preparations.'),
('a13', 'Atazanavir (ATV, Reyataz)', 'Atazanavir', '', '(Powder packet): 50 mg/packet','(Capsules): 150 mg, 200 mg, 300 mg (Powder packet): 50 mg/packet Note: Capsules and powder packets are not interchangeable.','(Capsules): 150 mg, 200 mg, 300 mg\r\n(Powder packet): 50 mg/packet\r\n\r\nNote: Capsules and powder packets are not interchangeable.', '[Evotaz] Atazanavir 300 mg + Cobicistat 150 mg', '', 'not approved', 'Powder Formulation: Powder formulation must be administered with ritonavir.\r\nweight 5 kg to below 15 kg: Atazanavir 200 mg (4 packets) + ritonavir \r\n80 mg (5 mL oral solution) both once daily with food.\r\nweight 15 to below 25 kg: Atazanavir 250 mg (5 packets) + ritonavir \r\n80 mg (5 mL oral solution) both once daily with food.\r\n\r\nCapsule formulation not approved', 'Atazanavir Powder\r\nweight 5 kg to below 15 kg: Atazanavir 200 mg (4 packets) + ritonavir \r\n80 mg (5 mL oral solution) both once daily with food.\r\nweight 15 to below 25 kg: Atazanavir 250 mg (5 packets) + ritonavir \r\n80 mg (5 mL oral solution) both once daily with food.\r\n\r\nCapsule formulation not approved', 'Atazanavir Capsules\r\nweight below 15 kg: Capsules not recommended\r\n15 kg to below 20 kg: Atazanavir 150 mg + ritonavir^c 100 mg both once daily \r\nwith food\r\n20 kg to below 40 kg: Atazanavir 200 mg + ritonavir^c 100 mg both once \r\ndaily with food\r\n40 kg and over: Atazanavir 300 mg + ritonavir^c 100 mg both once daily with \r\nfood.', 'Antiretroviral-Naive Patients: \r\nAtazanavir 300 mg + Ritonavir 100 mg once daily with food.\r\n(Atazanavir 300 mg + Cobicistat 150 mg) or [Evotaz] once daily with food\r\nAtazanavir 400 mg once daily with food\r\nAntiretroviral-Experienced Patients:\r\nAtazanavir 300 mg + Ritonavir 100 mg both once daily with food\r\n(Atazanavir 300 mg + Cibicistat 150 mg) or [Evotaz] once daily with food\r\nAtazanavir in Combination with Efavirenz (Adults) in Treatment-Naive \r\nPatients Only:\r\nAtazanavir 400 mg + Ritonavir 100 mg + Efavirenz 600 mg all once daily at \r\nseperate times. ATV/r taken with food, efavirenz taken on empty stomach. \r\nEfavirenz should not be co-administered with Atazanavir.\r\nAtazanavir in Combination with TDF (Adults):\r\nAtazanavir 300 mg + Ritonavir 100 mg + TDF 300 mg all once daily with food\r\nAtazanavir 300 mg + Cobicistat 150 mg + TDF 300 mg all once daily with food\r\nOnly boosted atazanavir should be used in combination with TDF.', 'Administer atazanavir with food to enhance absorption. Capsules and powder packets \r\nare not interchangible. Do not open capsules.'),
('a26', 'Cobicistat (COBI, TYBOST)', 'Cobicistat', '', '','(Tablets): 150 mg','(Tablets): 150 mg', '[Stribild] Elvitegravir 150 mg + cobicistat 150 mg + emtricitabine 200 mg + TDF 300 mg \r\n[Genvoya] Elvitegravir 150 mg + cobicistat 150 mg + emtricitabine 200 mg + TAF 10 mg\r\n[Evotaz] Atazanavir 300 mg + cobicistat 150 mg\r\n[Prezcobix] Darunavir 800 mg + cobicistat 150 mg', '', '', '', '', '[Stribild] weight over 35 kg and Tanner stage 4 or 5: one tablet once a day in \r\ntreatment-naive or virologically surpressed adults with a meal.\r\n[Genvoya] 35 kg or above and aged at least 12 years: one tablet once a day with \r\nfood in ARV treatment-naive patients or to replace the current ARV regimen in \r\nthose who are virologically suppressed (HIV-1 RNA under 50 copies/mL) on \r\na stable ARV regimen for at least 6 months with no history of treatment failure and \r\nno known substitutions associated with resistance to the individual components \r\nof Genvoya.', '[Stribild] one tablet once a day in treatment-naive or virologically \r\nsurpressed adults with a meal.\r\n[Genvoya] 35 kg or above and aged at least 12 years: one tablet once a day with \r\nfood in ARV treatment-naive patients or to replace the current ARV regimen in \r\nthose who are virologically suppressed (HIV-1 RNA under 50 copies/mL) on \r\na stable ARV regimen for at least 6 months with no history of treatment failure and \r\nno known substitutions associated with resistance to the individual components \r\nof Genvoya.', '');
INSERT INTO `medication_table` (`CName`, `Name`, `SName`, `Type`, `Formulations (Suspension)`, `Formulations (Tablet)`, `Formulations (BOTH)`,`Fixed Dose Combination Tablets`, `Treatment of HIV Infection`, `Neonate (birth to <3 months)`, `Infant (3 months to 8 months)`, `Pediatric (8 months to 6 years old)`, `Adolescent (6 years old - 17 years old)`, `Adult (18 years old+)`, `Special Instructions`) VALUES
('a27', 'Ritonavir (RTV, Norvir)', 'Ritonavir', '', '(Oral Solution (Contains 43% Alcohol by Volume)): 80 mg/mL','(Capsules): 100 mg (Tablets): 100 mg','(Oral Solution (Contains 43% Alcohol by Volume)): 80 mg/mL\r\n(Capsules): 100 mg\r\n(Tablets): 100 mg', '', '', '', '', '', '', '', '');

/*!40101 SET CHARACTER_SET_CLIENT=@OLD_CHARACTER_SET_CLIENT */;
/*!40101 SET CHARACTER_SET_RESULTS=@OLD_CHARACTER_SET_RESULTS */;
/*!40101 SET COLLATION_CONNECTION=@OLD_COLLATION_CONNECTION */;
